Literature DB >> 10699484

Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.

C J van Moorsel1, A M Bergman, G Veerman, D A Voorn, V W Ruiz van Haperen, J R Kroep, H M Pinedo, G J Peters.   

Abstract

To gain a more detailed insight into the metabolism of 2', 2'-difluoro-2'-deoxycytidine (dFdC, gemcitabine, Gemzar) and its effect on normal ribonucleotide (NTP) metabolism in relation to sensitivity, we studied the accumulation of dFdCTP and the changes in NTP pools after dFdC exposure in a panel of 21 solid tumour and leukaemia cell lines. Both sensitivity to dFdC and accumulation of dFdCTP were clearly cell line-dependent: in this panel of cell lines, the head and neck cancer (HNSCC) cell line 22B appeared to be the most sensitive, whereas the small cell lung cancer (SCLC) cell lines were the least sensitive to dFdC. The human leukaemia cell line CCRF-CEM accumulated the highest concentration of dFdCTP, whereas the non-SCLC cell lines accumulated the least. Not only the amount of dFdCTP accumulation was clearly related to the sensitivity for dFdC (R=-0.61), but also the intrinsic CTP/UTP ratio (R=0.97). NTP pools were affected considerably by dFdC treatment: in seven cell lines dFdC resulted in a 1.7-fold depletion of CTP pools, in two cell lines CTP pools were unaffected, but in 12 cell lines CTP pools increased about 2-fold. Furthermore, a 1.6-1.9-fold rise in ATP, UTP and GTP pools was shown in 20, 19 and 20 out of 21 cell lines, respectively. Only the UTP levels after treatment with dFdC were clearly related to the amount of dFdCTP accumulating in the cell (R=0.64 (P<0.01)), but not to the sensitivity to dFdC treatment. In conclusion, we demonstrate that besides the accumulation of dFdCTP, the CTP/UTP ratio was clearly related to the sensitivity to dFdC. Furthermore, the UTP levels and the CTP/UTP ratio after treatment were related to dFdCTP accumulation. Therefore, both the CTP and UTP pools appear to play an important role in the sensitivity to dFdC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699484     DOI: 10.1016/s0304-4165(99)00209-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  Analysis of deoxyribonucleotide pools in human cancer cell lines using a liquid chromatography coupled with tandem mass spectrometry technique.

Authors:  Wei Zhang; Shenglan Tan; Elijah Paintsil; Ginger E Dutschman; Elizabeth A Gullen; Edward Chu; Yung-Chi Cheng
Journal:  Biochem Pharmacol       Date:  2011-05-18       Impact factor: 5.858

2.  Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.

Authors:  Marie Morfouace; Anang Shelat; Megan Jacus; Burgess B Freeman; David Turner; Sarah Robinson; Frederique Zindy; Yong-Dong Wang; David Finkelstein; Olivier Ayrault; Laure Bihannic; Stephanie Puget; Xiao-Nan Li; James M Olson; Giles W Robinson; R Kiplin Guy; Clinton F Stewart; Amar Gajjar; Martine F Roussel
Journal:  Cancer Cell       Date:  2014-03-27       Impact factor: 31.743

3.  EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer.

Authors:  Michael J Levy; Steven R Alberts; William R Bamlet; Patrick A Burch; Michael B Farnell; Ferga C Gleeson; Michael G Haddock; Michael L Kendrick; Ann L Oberg; Gloria M Petersen; Naoki Takahashi; Suresh T Chari
Journal:  Gastrointest Endosc       Date:  2016-11-23       Impact factor: 9.427

4.  Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360).

Authors:  Godefridus J Peters; Kees Smid; Leonardo Vecchi; Ietje Kathmann; Dzjemma Sarkisjan; Richard J Honeywell; Nienke Losekoot; Osnat Ohne; Aric Orbach; Eran Blaugrund; Lak Shin Jeong; Young Bok Lee; Chang-Ho Ahn; Deog Joong Kim
Journal:  Invest New Drugs       Date:  2013-09-19       Impact factor: 3.850

5.  Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.

Authors:  Liang Li; Brooke Fridley; Krishna Kalari; Gregory Jenkins; Anthony Batzler; Stephanie Safgren; Michelle Hildebrandt; Matthew Ames; Daniel Schaid; Liewei Wang
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

6.  The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.

Authors:  Bea Pauwels; Annelies E C Korst; Greet G O Pattyn; Hilde A J Lambrechts; Juliette A E Kamphuis; Christel M J De Pooter; Godefridus J Peters; Filip Lardon; Jan B Vermorken
Journal:  BMC Cancer       Date:  2006-05-30       Impact factor: 4.430

7.  Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines.

Authors:  J R Kroep; G Giaccone; C Tolis; D A Voorn; W J Loves; C J Groeningen; H M Pinedo; G J Peters
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

8.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Authors:  A M Bergman; H M Pinedo; I Talianidis; G Veerman; W J P Loves; C L van der Wilt; G J Peters
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

9.  Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.

Authors:  E Giovannetti; V Mey; R Danesi; F Basolo; S Barachini; M Deri; M Del Tacca
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

10.  Effects of antibiotic antitumor drugs on nucleotide levels in cultured tumor cells: an exploratory method to distinguish the mechanisms of antitumor drug action based on targeted metabolomics.

Authors:  Fang Wang; Xi Liu; Cuichai Liu; Zheng Liu; Lixin Sun
Journal:  Acta Pharm Sin B       Date:  2015-04-08       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.